Impact of a vegan diet and lifestyle changes on indolent lymphoma during watchful waiting
Effect of Vegan Diet and Lifestyle Changes on the Course and Progression of Indolent Lymphoma During Controlled Waiting Period
This study is testing whether a vegan diet and lifestyle changes can help people with slow-growing lymphoma feel better and manage their condition during a watchful waiting period.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tel Aviv) |
| Trial ID | NCT04957693 on ClinicalTrials.gov |
What this trial studies
This trial evaluates how a vegan diet and lifestyle modifications affect the progression of indolent lymphomas during a watchful waiting period. Participants will engage in a structured program that includes vegan nutrition, aerobic physical activity, and stress reduction techniques such as relaxation and meditation. Over three years, the study will monitor various health parameters, including disease burden, symptoms, blood tests, body weight, and overall well-being. The outcomes of the intervention group will be compared to a control group receiving no intervention to assess the effectiveness of these lifestyle changes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with low-grade indolent lymphoma who do not require immediate treatment.
Not a fit: Patients requiring therapeutic intervention or those with other malignancies or chronic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive method to manage indolent lymphoma and improve patients' quality of life.
How similar studies have performed: While lifestyle interventions have been explored in various cancer contexts, this specific approach focusing on vegan diet and lifestyle changes in indolent lymphoma is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * Patient sex - male and female * Diagnosis with indolent lymphoma in low-grade lymphoma (follicular lymphoma (FL), marginal zone lymphoma MZL), as assessed by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria * Lack of need and non treatable patients at the time of diagnosis * Existence of detailed medical information about physical activity and dietary habits * Patients who have signed an informed consent form to participate in the study. Exclusion Criteria: * Need for therapeutic intervention * Administration of chemotherapy and / or monoclonal antibodies or immunomodulatory preparation * Chronic inflammatory or infectious disease * Another malignant disease * Pregnant women, special populations - children and incapacitated of judgment
Where this trial is running
Tel Aviv
- Tel-Aviv Sourasky Medical Center — Tel Aviv, Israel (Recruiting)
Study contacts
- Study coordinator: Irit Avivi, Prof'
- Email: iritavi@tlvmc.gov.il
- Phone: 03-6943782
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.